한글목차

세계의 미세잔존질환 검사 시장 규모는 2023년 22억 달러에서 예측 기간 중 14.3%의 CAGR로 추이하며, 2028년에는 43억 달러 규모로 성장할 것으로 예측됩니다.

기술별로 보면 중합효소 연쇄 반응(PCR) 부문은 2023년 9억 9,590만 달러에서 예측 기간 중 14.5%의 CAGR로 추이하며, 2028년에는 약 20억 달러 규모로 성장할 것으로 예측됩니다. 또한 차세대 시퀀싱(NGS) 부문은 2023년 3억 7,680만 달러에서 15.1%의 CAGR로 추이하며, 2028년에는 7억 6,230만 달러 규모로 성장할 것으로 예측됩니다.

세계의 미세잔존질환 검사 시장을 조사했으며, 시장 및 기술 배경, 시장 영향요인 및 시장 기회 분석, 시장 규모의 추이·예측, 각종 구분·지역별 상세 분석, 신규 기술의 동향, 특허 동향, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 요약·하이라이트

• 시장 전망

제3장 시장 개요

• 미세잔존질환의 정의
• 미세잔존질환 검출의 중요성
• 미세잔존질환 검사의 적응
• 미세잔존질환의 검출에 사용되는 기술

제4장 시장 역학

• 시장 역학
• 촉진요인
• 억제요인
• 기회
• 미세잔존질환 검사 시장에 대한 COVID-19의 영향
• 법규제 상황
• 1988년 임상 검사 개선 수정(CLIA)
• 주 라이선싱 법
• 미국 FDA

제5장 세계의 미세잔존질환 검사 시장 : 기술별

• 개요
• 유세포분석
• 중합효소 연쇄 반응(PCR)
• 차세대 시퀀싱(NGS)
• 기타

제6장 세계의 미세잔존질환 검사 시장 : 용도별

• 개요
• 혈액 악성 종양
• 백혈병
• 림프종
• 골수종
• 고형 종양
• 기타

제7장 세계의 미세잔존질환 검사 시장 : 지역별

• 북미
• 유럽
• 아시아태평양
• 기타 지역

제8장 ESG 도입

• 미세잔존질환 검사 업계에서 ESG의 중요성
• ESG 평가와 지표 : 데이터의 이해
• 미세잔존질환 검사 업계에서 ESG의 실천
• 환경면 퍼포먼스
• 사회면 퍼포먼스
• 거버넌스면 퍼포먼스
• 향후 동향
• BCC Research의 견해

제9장 새로운 기술과 개발

• 신기술
• 디지털 중합효소 연쇄 반응(dPCR)

제10장 M&A 분석

제11장 경쟁 정보

• 주요 기업 순위
• 기업의 주요 전략
• 협업
• 마케팅 활동
• 신제품 발매
• 확장
• 취득
• 파트너십·협력·제휴
• 임상 데이터 연구
• 기타

제12장 기업 개요

• ADAPTIVE BIOTECHNOLOGIES CORP.
• AMGEN INC.
• ASTRAZENECA PLC
• BIO-RAD LABORATORIES INC.
• CERGENTIS B.V.
• EXACT SCIENCES CORP.
• GUARDANT HEALTH INC.
• ILLUMINA INC.(GRAIL LLC)
• INVITAE
• INVIVOSCRIBE INC.
• NATERA INC.
• NEOGENOMICS INC.
• QIAGEN
• SYSMEX CORP.

영문목차

Highlights:

The global market for minimal residual disease testing is estimated to increase from $2.2 billion in 2023 to reach $4.3 billion by 2028, at a compound annual growth rate (CAGR) of 14.3% from 2023 through 2028.

The global market for polymerase chain reaction for minimal residual disease testing is estimated to increase from $995.9 million in 2023 to reach about $2.0 billion by 2028, at a CAGR of 14.5% from 2023 through 2028.

The global market for next-generation sequencing (NGS) for minimal residual disease testing is estimated to increase from $376.8 million in 2023 to reach $762.3 million by 2028, at a CAGR of 15.1% from 2023 through 2028.

Report Scope:

The report's scope includes an overview of the global market on minimal residual disease testing and an analysis of global market trends, using 2022 as the base year and forecasting 2023 through 2028 with a compound annual growth rate (CAGR) projection.

The report analyzes leading and emerging technologies, applications, end-user, and product pipeline details for minimal residual disease testing. Profiles of leading market players, their specific products, financial information, and recent market activities are provided. This report also assesses companies' mergers and acquisitions and funding activities and their impact in the face of the competitive environment. The report details the minimal residual disease testing market based on technology, application, and end user. The market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others based on technology.

The market is categorized as hematological malignancies [leukemia, lymphoma (non-Hodgkin lymphoma, Hodgkin lymphoma), myeloma], solid tumors, and others based on application. The report also considers the impact of the Covid-19 pandemic on this market. Regional analysis includes North America (U.S., Canada, and Mexico), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the World (South America and the Middle East and Africa).

Report Includes:

• 44 data tables and 45 additional tables
• An up-to-date overview and in-depth analysis of the global markets for minimal residual disease (MRD) testing
• Analyses of the global market trends, historical market revenue (sales figures) data from 2021-2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028
• Estimation of the actual market size and revenue forecast for global minimal residual disease testing market in USD million values, and corresponding market share analysis based on technology, application, and region
• In-depth information (facts and figures) concerning the market growth drivers, opportunities and challenges, prospects, technologies, regulatory scenarios, and the impact of COVID-19 on the progress of this market
• Detailed description of specific somatic or germline mutations that serve as precise markers to diagnose cancer during ongoing investigations
• Coverage of major cancers such as leukemia, lymphoma, and multiple myeloma, and discussion on how MRD level monitoring enables more precise evaluations, thereby identifying the amount of risk or enabling early prevention of future relapse
• Discussion of the importance of ESG in global minimal residual disease testing market, consumer attitudes, risks and opportunity assessment, future trends, and ESG followed practices within the industry
• A look at the major vendors in minimal residual disease testing market, and analyze the structure of this industry with respect to company market shares, venture fundings, and recent merger and acquisition (M&A) activities
• Identification of the major stakeholders and analysis of their company competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
• Detailed company profiles of the leading market players, including Adaptive Biotechnologies, Invitae Corp., Guardant Health, Natera Inc., NeoGenomics Inc., Exact Sciences Corp., and Quest Diagnostics

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Research Methodology
• Information Sources
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Outlook

Chapter 3 Market Overview

• Definition of Minimal Residual Disease
• Importance of Detecting Minimal Residual Disease
• Indications for Minimal Residual Disease Testing
• Techniques Used for Detecting Minimal Residual Disease

Chapter 4 Market Dynamics

• Market Dynamics
• Drivers
• Restraints
• Opportunities
• Impact of Covid-19 on Minimal Residual Disease Testing Market
• Regulatory Landscape
• Clinical Laboratory Improvement Amendments of 1988 (CLIA)
• State Licensing Laws
• The U.S. Food and Drug Administration

Chapter 5 Global Minimal Residual Disease Testing Market by Technology

• Overview
• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Others

Chapter 6 Global Minimal Residual Disease Testing Market by Application

• Overview
• Hematological Malignancies
• Leukemia
• Lymphoma
• Myeloma
• Solid Tumors
• Others

Chapter 7 Global Minimal Residual Disease Testing Market by Region

• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 8 ESG Developments

• Importance of ESG in Minimal Residual Disease Testing Industry
• ESG Ratings and Metrics: Understanding the Data
• ESG Practices in the Minimal Residual Disease Testing Industry
• Environmental Performance
• Social Performance
• Governance Performance
• Future Trends
• BCC Research Viewpoint

Chapter 9 Emerging Technologies and Developments

• Emerging Technologies
• Digital Polymerase Chain Reaction (dPCR)

Chapter 10 M&A Analysis

• M&A Analysis

Chapter 11 Competitive Intelligence

• Top Market Players Ranking, 2022
• Key Strategies Adopted by Companies
• Collaborations
• Marketing Activity
• New Product Launch
• Expansion
• Acquisition
• Partnerships, Agreements and Alliances
• Clinical Data Studies
• Others

Chapter 12 Company Profiles

• ADAPTIVE BIOTECHNOLOGIES CORP.
• AMGEN INC.
• ASTRAZENECA PLC
• BIO-RAD LABORATORIES INC.
• CERGENTIS B.V.
• EXACT SCIENCES CORP.
• GUARDANT HEALTH INC.
• ILLUMINA INC. (GRAIL LLC)
• INVITAE
• INVIVOSCRIBE INC.
• NATERA INC.
• NEOGENOMICS INC.
• QIAGEN
• SYSMEX CORP.